“…Agents that preferentially inhibit class I HDACs, such as sodium butyrate (NaB), trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA), and valproic acid (VPA), relax chromatin structure, which allows for increased readout of genes associated with synaptic plasticity and memory formation, in addition to acting on non-histone targets to stimulate signaling pathways [14,17,39,42]. Pharmacological inhibition of HDACs facilitates long-term potentiation (LTP) in the CA1 area of the dorsal hippocampus, enhances the formation and extinction of memory for fearmotivated tasks [6,9,29,30,55,57], and attenuates memory impairments in aging and models of neurodegenerative disorders [3,8,27,41,44].…”